Overview

Lowering Uric Acid in Live Kidney Donors

Status:
Completed
Trial end date:
2020-09-25
Target enrollment:
Participant gender:
Summary
Recently there was described an increase in left ventricular mass after kidney donation. It is uncertain whether this is reversible or not. Allopurinol lowers uric acid in the blood and is normally indicated for gout, but studies have showed that it also can reduce the thickness of the left ventricle of the heart in people with heart- and kidney disease. The investigators wish to give allopurinol or placebo to kidney donors based on randomization and investigate if this has the same effect on kidney donors. The investigators are assessing this by performing a cardiac MRI at baseline and after 9 months of treatment. In addition the investigators wish to see if allopurinol can have beneficial effects on blood pressure and insulin sensitivity as well.
Phase:
Phase 2
Details
Lead Sponsor:
Oslo University Hospital
Collaborators:
South-Eastern Norway Regional Health Authority
University of Oslo
Treatments:
Allopurinol
Uric Acid